Designing a tumor landscape-modifying vaccine with a unique TLR2/6 agonist for refractory pancreatic cancer.

In a KPC orthotopic pancreatic cancer model with the KRAS G12D mutation, the C-VAX integrated vaccine increased CD8a T-cell infiltration and reduced α-SMA expression in the tumor microenvironment.

• Why it matters: Cancer vaccine failures in trials are linked to immunosuppressive tumor microenvironments, poor antigen delivery, limited human MHC antigenicity, and unsafe or suboptimal adjuvants, limiting preclinical translatability.
• What they did: The study engineered C-VAX from the natural TLR2/6 agonist UNE-C1, covalently linked it to a KRAS G12D neoantigen and WNT5a, then tested efficacy in the KPC orthotopic model and combined it with anti-PD-1.
• The result: The vaccine promoted an immune-responsive tumor microenvironment, and its therapeutic effects were further enhanced by anti-PD-1 checkpoint blockade, supporting targeting both tumor antigens and resistance-associated TME components.